Frontiers in Psychology
June 9, 2015
Norman A. S. Farb, Jennifer Daubenmier, Cynthia Price et al.
630 citations
Interoception, the sense of internal bodily signals, is essential for embodiment, motivation, and well-being but remains poorly understood. This review integrates perspectives from neuroscience, clinical practice, and contemplative studies, introducing an expanded taxonomy of interoceptive processes. It argues that many of these processes can be explained by a predictive coding model of mind-body integration, which describes tension between expected and felt body sensations. This model parallels contemplative theories and links interoception to affective and psychosomatic disorders. Maladaptive interpretation of bodily sensations may underlie many contemporary maladies, and contemplative practices may reduce these biases, restoring a sense of presence and agency.
Psychopharmacology
January 2, 2019
Thomas Anderson, Rotem Petranker, Daniel Rosenbaum et al.
171 citations
No Summary
November 1, 2018
Thomas Anderson, Rotem Petranker, Daniel M. Rosenbaum et al.
11 citations
preprint
People who regularly consume small amounts of psychedelics like LSD or psilocybin—a practice called microdosing—report lower levels of dysfunctional attitudes and negative emotionality, and higher levels of wisdom, open-mindedness, and creativity compared to those who do not microdose. This pre-registered study, the first to investigate microdosing and mental health, recruited participants from online forums. Although promising, the findings are preliminary and warrant controlled experimental research to test safety and clinical efficacy. Microdosing may offer clinical benefits without the hallucinogenic effects of full-dose psychedelic therapy.
April 8, 2024
Saampras Ganesan, Aki Tsuchiyagaito, Greg J. Siegle et al.
2 citations
preprint
Meditation practices, which have been adapted into manualized interventions for conditions like depression, pain, addiction, and anxiety, show therapeutic promise, but their neuroscientific basis remains unclear. Current neuroimaging studies rely on small, heterogeneous datasets that vary in practice types, participant experience, clinical targets, and imaging methods, limiting generalizability and replicability. To address this, the ENIGMA-Meditation consortium was formed as a global collaboration to conduct systematic meta- and mega-analyses of distributed neuroimaging data using standardized methods. This framework aims to improve statistical power and rigorously characterize the neural mechanisms underlying meditation's effects on psychological and cognitive attributes, advancing the field of contemplative neuroscience.
November 16, 2025
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
preprint
A phase II trial will test whether microdosing psilocybin (2 mg weekly) outperforms placebo for major depressive disorder. Forty adults will receive either psilocybin or placebo for four weeks, then all will receive psilocybin for another four weeks. Depression symptoms and other measures will be assessed at baseline, after four weeks, and after eight weeks, with follow-ups for two years. The study aims to clarify whether microdosing has genuine antidepressant effects or whether benefits are due to expectancy, and to inform future dose regimens and the therapeutic role of sub-threshold versus threshold doses.